TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12540401

Group type: EXPERIMENTAL
Intervention: Cold exposure (physical stress)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Arithmetic calculations (mental stress)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dark exposure (emotional stress)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diurnal variations in nicotinamide metabolites
Number of subjects: 12
Study: 10759821

Group type: EXPERIMENTAL
Intervention: 5% 5‐FU in a PC vehicle (cream A)
Number of subjects: 13

Group type: COMPARATOR
Intervention: 5% 5‐FU in a petrolatum base (cream B)
Number of subjects: 13
Study: 9322481

Group type: EXPERIMENTAL
Intervention: Chlorzoxazone (500 mg orally on the morning of surgery)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no chlorzoxazone administration)
Number of subjects: 30
Study: 8445418

Group type: EXPERIMENTAL
Intervention: Carboplatin (400 mg/m2)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Whole-abdominal radiotherapy (24 Gy)
Number of subjects: 254
Study: 3781021

Group type: EXPERIMENTAL
Intervention: Low-dose bromocriptine (1.25 to 2.5 mg) at bedtime for the first 18 days of the cycle (Group A)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Bromocriptine (similar to Group A) with clomiphene citrate (Group C)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Pyridoxine (100 mg continuously) (Group B)
Number of subjects: 43
Study: 30201202

Group type: EXPERIMENTAL
Intervention: Mindfulness-based psychoeducation program
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135
Study: 26967831

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: intubation
Number of subjects: 50
Study: 24789134

Group type: EXPERIMENTAL
Intervention: Goal-directed hands-on training session (Sim group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Unstructured hands-on session (control group)
Number of subjects: 56
Study: 22624289

Group type: EXPERIMENTAL
Intervention: Active head-tilt condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural head-tilt condition
Number of subjects: 0
Study: 20156908

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg) plus Lapatinib (1,500 mg)
Number of subjects: 1286

Group type: COMPARATOR
Intervention: Letrozole (2.5 mg) plus Placebo
Number of subjects: 1286
Study: 18577934

Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small dosages of amitriptyline and fluvoxamine with transcranial electrostimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of antidepressants with transcranial electrostimulation
Number of subjects: 0
Study: 15784061

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 200
Study: 11450419

Group type: EXPERIMENTAL
Intervention: One-stage cylindrical screw implants with a synthetic bone substitute
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hollow screw-type implants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solid screw-type implants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One-stage implant osseointegration with synthetic graft material
Number of subjects: 0
Study: 9669455

Group type: EXPERIMENTAL
Intervention: Betaine-containing toothpaste (4% betaine)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Regular toothpaste (without betaine)
Number of subjects: 13
Study: 8114833

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 72
Study: 3043555

Group type: EXPERIMENTAL
Intervention: Ceruletide (0.8 micrograms/kg, intramuscular injections, once weekly for 4 weeks)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (intramuscular injections, once weekly for 4 weeks)
Number of subjects: 37
Study: 8230622

Group type: EXPERIMENTAL
Intervention: Active antiarrhythmic drug therapy (encainide, flecainide, moricizine)
Number of subjects: 3549

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3549
Study: 681543

Group type: EXPERIMENTAL
Intervention: Low dose marihuana
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High dose marihuana
Number of subjects: 48

Group type: COMPARATOR
Intervention: Coltsfoot
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 31053619

Group type: EXPERIMENTAL
Intervention: Custom-made acrylic titratable MAD (TALI)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Thermoplastic heat-moulded titratable MAD (ONIRIS)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 198
Study: 27923264

Group type: EXPERIMENTAL
Intervention: Abstinent Contingent Group (AC)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Submission Contingent Group (SC)
Number of subjects: 94
Study: 25572623

Group type: EXPERIMENTAL
Intervention: Greater frequency of receiving 5A instruction
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Perception of preceptors as excellent role models in tobacco treatment
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Greater 5A instruction
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Observation of tobacco treatment
Number of subjects: 1065
Study: 23228172

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg) plus prednisone (5 mg twice daily)
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Placebo plus prednisone
Number of subjects: 1088
Study: 21750078

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 19574407

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524

Group type: COMPARATOR
Intervention: Standard Smoking Cessation CBT
Number of subjects: 524
Study: 17132719

Group type: EXPERIMENTAL
Intervention: Full-dose cyclophosphamide (3.3 g/m2)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Half-dose cyclophosphamide (1.65 g/m2)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: With maintenance course M1
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Without maintenance course M1
Number of subjects: 637
Study: 15529609

Group type: EXPERIMENTAL
Intervention: Diosmectite 3 g b.i.d.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Loperamide 2 mg b.i.d.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 50
Study: 11167469

Group type: EXPERIMENTAL
Intervention: Midazolam 0.025 mg x kg(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg x kg(‐1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study: 9596231

Group type: EXPERIMENTAL
Intervention: Stroke unit treatment
Number of subjects: 220

Group type: COMPARATOR
Intervention: General wards treatment
Number of subjects: 220
Study: 7811050

Group type: EXPERIMENTAL
Intervention: Cefprozil 15 mg/kg
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Cefprozil 20 mg/kg
Number of subjects: 89
Study: 3293253

Group type: EXPERIMENTAL
Intervention: Laser therapy combined with indomethacin at a daily dose of 75-100 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Laser therapy alone
Number of subjects: 33
Study: 31989965

Group type: EXPERIMENTAL
Intervention: Strengthening and stretching exercises
Number of subjects: 619

Group type: COMPARATOR
Intervention: Deep tissue massage
Number of subjects: 619

Group type: COMPARATOR
Intervention: Combined therapy (massage and exercises)
Number of subjects: 619

Group type: COMPARATOR
Intervention: Advice to stay active
Number of subjects: 619
Study: 29304245

Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27562777

Group type: EXPERIMENTAL
Intervention: Unhealthy snack
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Fruit
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Snack-fruit condition
Number of subjects: 108

Group type: COMPARATOR
Intervention: Fruit-snack condition
Number of subjects: 108

Group type: COMPARATOR
Intervention: Reward sensitivity
Number of subjects: 108
Study: 24866279

Group type: EXPERIMENTAL
Intervention: Conventional colporrhaphy and mesh repair surgery
Number of subjects: 164
Study: 22331405

Group type: EXPERIMENTAL
Intervention: Intervention (at least four group sessions)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Intervention (high attendance)
Number of subjects: 198
Study: 21112904

Group type: EXPERIMENTAL
Intervention: Combined aerobic and strength training (twice a week for 20 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combined aerobic and strength training
Number of subjects: 16
Study: 19440326

Group type: EXPERIMENTAL
Intervention: Early ART (initiated within 14 days of starting acute OI treatment)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Deferred ART (initiated after acute OI treatment is completed)
Number of subjects: 282
Study: 16477653

Group type: EXPERIMENTAL
Intervention: Vt = 5 ml/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vt = 3 ml/kg
Number of subjects: 30
Study: 15023577

Group type: EXPERIMENTAL
Intervention: Nonpsychotic relatives of persons with schizophrenia
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 24
Study: 11800144

Group type: EXPERIMENTAL
Intervention: 30mg acitretin daily
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 9483596

Group type: EXPERIMENTAL
Intervention: suxamethonium 1.0 mg.kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: rocuronium 0.6 mg.kg‐1
Number of subjects: 60
Study: 7848890

Group type: EXPERIMENTAL
Intervention: IV vinorelbine (30 mg/m2 weekly)
Number of subjects: 54
Study: 3184107

Group type: EXPERIMENTAL
Intervention: Thrice daily hydrocortisone replacement
Number of subjects: 7

Group type: COMPARATOR
Intervention: Twice daily hydrocortisone replacement
Number of subjects: 7
Study: 30193001

Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg)/vitamin B12 (0.4 mg)/vitamin B6 (40 mg)
Number of subjects: 2049

Group type: EXPERIMENTAL
Intervention: Folic acid/vitamin B12
Number of subjects: 2049

Group type: EXPERIMENTAL
Intervention: Vitamin B6
Number of subjects: 2049

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2049
Study: 29179765

Group type: EXPERIMENTAL
Intervention: Peer advocates disclosing personal details about their lives
Number of subjects: 5
Study: 26387934

Group type: EXPERIMENTAL
Intervention: Oocyte retrieval at 36 hours post-HCG administration (n = 78)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Oocyte retrieval at 38 hours post-HCG administration (n = 78)
Number of subjects: 156
Study: 22849970

Group type: EXPERIMENTAL
Intervention: Low-fat/low-saturated fat/low-glycaemic index diet (LSAT: 23% fat, 7% saturated fat, GI < 55)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-fat/high-saturated fat/high-glycaemic index diet (HSAT: 43% fat, 24% saturated fat, GI > 70)
Number of subjects: 20
Study: 21493302

Group type: EXPERIMENTAL
Intervention: Postoperative nasal packing in patients with mild OSA (RDI <15)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Postoperative nasal packing in patients with moderate/severe OSA (RDI ≥15)
Number of subjects: 49
Study: 19660597

Group type: EXPERIMENTAL
Intervention: Infarct size estimated by peak serum CK-MB concentration
Number of subjects: 3491
Study: 16411990

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 9996

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate for severe pre-eclampsia
Number of subjects: 9996
Study: 15257791

Group type: EXPERIMENTAL
Intervention: 80 mg loading dose of beta-artemether
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: 160 mg loading dose of beta-artemether
Number of subjects: 223
Study: 11567707

Group type: EXPERIMENTAL
Intervention: Chemoprevention treatment trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk-reducing mastectomy (RRM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI breast screening
Number of subjects: 0
Study: 9304981

Group type: EXPERIMENTAL
Intervention: Modified one-day bowel cleaning
Number of subjects: 48

Group type: COMPARATOR
Intervention: Traditional three-day bowel preparation
Number of subjects: 48
Study: 8465173

Group type: EXPERIMENTAL
Intervention: Toluene exposure at 2 mg.min-1 for 3 hours
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Toluene exposure at 6 mg.min-1 for 30 minutes
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ethanol ingestion at 0.08 g.kg-1 during toluene exposure at 2 mg.min-1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ethanol ingestion at 0.16 g.kg-1 during toluene exposure at 2 mg.min-1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ethanol ingestion at 0.32 g.kg-1 during toluene exposure at 2 mg.min-1
Number of subjects: 8
Study: 3810714

Group type: EXPERIMENTAL
Intervention: Ethanol administration
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 26
Study: 31036759

Group type: EXPERIMENTAL
Intervention: Magnesium oxide (MgO)
Number of subjects: 125

Group type: COMPARATOR
Intervention: AST-120
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control
Number of subjects: 125
Study: 29885163

Group type: EXPERIMENTAL
Intervention: Oral vitamin D along with metformin
Number of subjects: 140

Group type: COMPARATOR
Intervention: Metformin only
Number of subjects: 140
Study: 25231596

Group type: EXPERIMENTAL
Intervention: Early pregnancy urinary metabolomic profile
Number of subjects: 50
Study: 24445832

Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes with adenoidectomy
Number of subjects: 159

Group type: COMPARATOR
Intervention: Neither intervention (control group)
Number of subjects: 159
Study: 23205751

Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resistance exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 0
Study: 19505384

Group type: EXPERIMENTAL
Intervention: Aerosol treatment with thiamphenicol glycinate acetylcysteinate (250 mg/day in 2 administrations) plus beclomethasone (400 microg/day in 2 administrations) for 10 days/month over a period of 6 months.
Number of subjects: 204

Group type: COMPARATOR
Intervention: No treatment (control group).
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Aerosol treatment with thiamphenicol glycinate acetylcysteinate plus beclomethasone.
Number of subjects: 204
Study: 17126337

Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone (300 mg daily for 6 weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Oral dydrogesterone (30 mg daily for 6 weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 53
Study: 15828052

Group type: EXPERIMENTAL
Intervention: Wheat bran
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei
Number of subjects: 398

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 398
Study: 12665046

Group type: EXPERIMENTAL
Intervention: Moclobemide 150 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moclobemide 300 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10193218

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg‐1
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Droperidol 20 micrograms.kg‐1
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.2 mg.kg‐1
Number of subjects: 180
Study: 7619569

Group type: EXPERIMENTAL
Intervention: Continuous treatment (dry powder inhalations of either salbutamol 1600 micrograms or ipratropium bromide 160 micrograms daily)
Number of subjects: 83

Group type: COMPARATOR
Intervention: On demand treatment (only during exacerbations or periods of dyspnoea)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Continuous treatment
Number of subjects: 83

Group type: COMPARATOR
Intervention: On demand treatment
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 83
Study: 1518167

Group type: EXPERIMENTAL
Intervention: Form A (16 questions)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Form B (39 questions)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Cancer patients
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Non-malignant disease patients
Number of subjects: 114
Study: 6391134

Group type: EXPERIMENTAL
Intervention: Intravenous timolol treatment
Number of subjects: 144

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 144
Study: 30797381

Group type: EXPERIMENTAL
Intervention: SBIRT
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: e‐SBIRT
Number of subjects: 439

Group type: COMPARATOR
Intervention: SBIRT and e‐SBIRT
Number of subjects: 439
Study: 29316143

Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Insulin glargine (GL)
Number of subjects: 15
Study: 27021514

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation training
Number of subjects: 35

Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 35
Study: 25237669

Group type: EXPERIMENTAL
Intervention: 11-mm implant combined with maxillary sinus floor elevation surgery
Number of subjects: 41

Group type: COMPARATOR
Intervention: 6-mm implant without any grafting
Number of subjects: 41
Study: 22945604

Group type: EXPERIMENTAL
Intervention: High CGA concentration (4525 μmol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medium CGA concentration (2219 μmol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low CGA concentration (1053 μmol)
Number of subjects: 0
Study: 19951722

Group type: EXPERIMENTAL
Intervention: Head Up Tilt (HUT)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mental Arithmetic (MA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mental Arithmetic + Head Up Tilt (MA+HUT)
Number of subjects: 16
Study: 18191521

Group type: EXPERIMENTAL
Intervention: Early-switch group received liposomal AmB after randomisation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Late-switch group received liposomal AmB only when sCr increase was >=100% or sCr reached 170mumol/L
Number of subjects: 32
Study: 15812080

Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin-radiotherapy (CRT)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 350
Study: 12775888

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 48
Study: 10635419

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once daily for 3 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Co-amoxiclav (625 mg thrice daily for 10 days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Co-amoxiclav
Number of subjects: 100
Study: 7926531

Group type: EXPERIMENTAL
Intervention: Low-osmolality, nonionic contrast agent (Omnipaque 300; iohexol, 672 mOsm/kg H2O)
Number of subjects: 690

Group type: COMPARATOR
Intervention: High-osmolality, ionic contrast agent (Hypaque 50%; diatrizoate sodium, 1515 mOsm/kg H20)
Number of subjects: 690
Study: 2684502

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 0
Study: 795256

Group type: EXPERIMENTAL
Intervention: Cimetidine (0.8 g daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30790446

Group type: EXPERIMENTAL
Intervention: Rosuvastatin treatment for 6 months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo treatment for 6 months
Number of subjects: 66
Study: 28641582

Group type: EXPERIMENTAL
Intervention: IV levetiracetam infusion (40 mg/kg over 5 min)
Number of subjects: 200

Group type: COMPARATOR
Intervention: IV phenytoin infusion (20 mg/kg over 20 min)
Number of subjects: 200
Study: 25801501

Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) 50 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 23906656

Group type: EXPERIMENTAL
Intervention: CP+BEV→BEV
Number of subjects: 0

Group type: COMPARATOR
Intervention: CP alone
Number of subjects: 0
Study: 21425181

Group type: EXPERIMENTAL
Intervention: Intrauterine transfusions (IUT) through the intrahepatic portion of the umbilical vein (IHV) or at the placental cord insertion (PCI)
Number of subjects: 25
Study: 18503138

Group type: EXPERIMENTAL
Intervention: Octostim nasal spray (300 mug)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 17
Study: 17027358

Group type: EXPERIMENTAL
Intervention: GnRH analogue (100 microg) administered to all individuals, followed by retesting of hormone levels after 4 hours.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: hCG administration for patients with beta-thalassemia and low T levels.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 33
Study: 12551795

Group type: EXPERIMENTAL
Intervention: Cold knife
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: LEEP
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Laser
Number of subjects: 110
Study: 10957698

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Amputation
Number of subjects: 120
Study: 8838438

Group type: EXPERIMENTAL
Intervention: Loperamide with cotrimoxazole (960 mg, twice daily for 24 h before and 48 h after administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loperamide oxide with cotrimoxazole (960 mg, twice daily for 24 h before and 48 h after administration)
Number of subjects: 0
Study: 8254650

Group type: EXPERIMENTAL
Intervention: Harassment condition
Number of subjects: 94

Group type: COMPARATOR
Intervention: Social Evaluation condition
Number of subjects: 94